Welcome to Impact China IV --
Welcome to Impact China IV: the conference bellwether for the Chinese pharmaceutical R&D industry. We look forward to seeing you in Beijing, May 4-6, 2008, for three days of education, collaboration and innovation!
Over the past four years, Impact China has attracted hundreds of your colleagues and clients. The ability to attract such a dynamic audience is due to unparalleled sessions lead by influential industry thought leaders and facilitated introductions between Western and Eastern pharmaceutical industry executives. Reserve your place early to ensure your seat among the industry’s elite.
|
Impact China IV is proud to announce a new addition to the 2008 program. Please join us for the newly added pre-conference workshop on May 4 at 3pm.
Ethics in Chinese Clinical Trials: A Roadmap for Sponsors and Researchers
This workshop presents a roadmap for effectively designing, conducting and registering clinical trials in China according to the highest ethical standards. A general overview of the ethical considerations in designing clinical trial protocols and submissions provides a general framework for understanding ethical review and informed consent in China. The workshop is designed to provide insight into how ethics committees function in China, and how to prepare successful applications to ethics committees alongside the application for clinical trial approval to the State Food & Drug Administration. It compares ethical review procedures in China with IRB-ERB review in the United States and Canada and ethics committee review in Europe. The workshop also gives some focus on informed consent procedures and form development for China, highlighting specific cultural and regional considerations.
Take away knowledge from this workshop includes:
- The general GCP and national guidelines affecting ethics and ethical review in China
- How to approach and submit successful applications to ethics committees in China
- Specific considerations on informed consent in China, process and forms
- The relationship between the ethics committees in China and the State Food & Drug Administration
- Ethical expertise in China: Where is it? and How to utilize it?
- Ethical considerations when preparing clinical trial protocols for China
Speakers:
Professor Yali Cong, Medical Ethics Program, Peking University Health Science Center, Forum for Ethical Review Committees in China (FERCIC)
Dr. Haitao (Heidi) Liu, Medical Officer, Forum for Ethical Review Committees in Asia & the Western Pacific, (FERCAP)
Francis P. Crawley, Executive Director, Good Clinical Practice Alliance – Europe (GCPA) |
Impact China IV Solutions:
As China continues its unprecedented growth, the question is no longer are you working in China but how are you working in China. The Chinese market continues to mature and now is the time to fully develop a decisive stratagem for accessing the market and realizing the benefits China offers.
Impact China has grown along with the market with its comprehensive coverage of vital issues and progressive business strategies. 2008 is no exception as special focus will be given to your essential interests and paramount concerns, including:
- Toxicology Outsourcing: The Growing Demand for Niche Specialties in China
- Conducting Clinical Trials in China
- Collaborations & Partnerships
- Reforms & Regulations
- CROS and Outsourcing to China
- Investors: Perspectives & Opportunities
- Generics & Quality Assurance
- Novel Advancements and Developments Originating in China
- Working in China: Options for Getting Business Done
- Incorporating Traditional Chinese Medicine into your Pipeline
Only at Impact China will you also find dedicated sessions covering:
- Competitive Models of Retail Pharmacy in China
- Innovations in the Global Economy
- Chinese SFDA and Global Drug Development – Quality, Science and Speed
Plus:
Policy and Regulations: Reactions on the Current Landscape: This unprecedented session featuring policy makers from the SFDA, RDPAC and the Ministry of Public Health, will address key regulatory issues along with insight for improving speed and performance.
Introducing the 2008 Impact China IV Speaker Faculty:
For 2008, Impact China has been elevated to its most senior level yet. As the pre-eminent event on the Chinese pharmaceutical market, Impact China IV offers you the foremost experts in the industry.
Please join us in welcoming:
Keynote Speakers:
- Nathan Collins, Ph.D., SRI International
- Cezary Statuch, M.D., Bristol-Myers Squibb China
- Rae Yuan, Ph.D., Roche China
Esteemed Speaker Faculty:
- Dr. Zhiqiang An, Merck Research Laboratories
- Steven Bottomley, Mayer Brown
- Sean Caffey, M.D., M.B.A., Biomimetic MicroElectronic Systems NSF Engineering Research Center, University of Southern California, CalTech and UC Santa Cruz
- Jason Chen, Cardinal Health
- Norman Chen, Fidelity Asia Ventures
- Shaoyu Chen, Amgen
- Vivian Chen, RDPAC
- Zhengming "Jimmy" Chen, Ph.D., DOV Pharmaceutical, Inc.
- Tao Cheng, M.D., University of Pittsburgh School of Medicine/ University of Pittsburgh Cancer Institute
- Matthew Chervenak, General Biologic
- Karen Chu, Parexel
- Professor Yali Cong, Peking University Health Science Center, Forum for Ethical Review Committees in China (FERCIC)
- Francis P. Crawley, Good Clinical Practice Alliance – Europe (GCPA)
- Paul Dai, M.D., Novartis China
- Hongkui Deng, Peking University
- Mark Engel, Excel PharmaStudies
- Zack Fang, ESI
- Jun Gu, Ph.D., M.D., Wadsworth Center, USA
- Yun He, Roche
- Dr. Ruediger Herrmann, Mayer Brown
- Min Irwin, M.D., Ph.D., Bayer HealthCare Company Ltd.
- Eita Kitayama, Synta Pharmaceuticals Corp.
- George Lankas, Ph.D., Amicus Therapeutics, Inc.
- Hai Chao Lei, Ministry of Public Health
- Jifeng Li, Shanghai Anbison Lab. Ltd. Co.
- Zili Li, M.D. MPH, Merck & Co, Inc.
- Allan (Riting) Liu, Ph.D., M.B.A., Wanbang Biopharm Co. Ltd./ Fosun Pharmaceutical (Group) Co., Ltd.
- ]Dr. Haitao (Heidi) Liu, Forum for Ethical Review Committees in Asia & the Western Pacific, (FERCAP)
|
- Janet Lu, BS, MSD China
- Ronald J.Marler, DVM, Ph.D., Bridge Laboratories
- D.Thomas Oakley, Bridge Laboratories
- Xuetao Pei, Beijing Institute of Transfusion Medicine
- Sofie Qiao, Ph.D., LEAD Therapeutics
- Carl Ren, China Monitor
- Jin Ren, M.D., Ph.D., Center for Drug Safety Evaluation & Research Shanghai Institute of Materia Medica Chinese Academy of Sciences
- Hironobu Saito, Ph.D., Daiichi Sankyo
- James J. Shen, Pharma China/ Wicon International Group
- Ray Shen, Beijing Elite
- Maria Song, Ph.D., M.D., VPSCRO Global Corp. Member of Venturepharm Group
- Val Su, Wyeth Pharmaceuticals
- Lai-Lee Tan, Quintiles
- Dr. Xiaoxiong "Jim" Wei, Medpace
- Jimmy Wei, Ph.D., M.B.A., Hutchison MediPharma
- Patrick C.K. Wong, Mayer Brown
- James Xin, Beijing Elite
- Tianpei Xie, M.D., Ph.D., Shanghai Standard Biotech Co. Ltd.
- Jia Qi Xu, SFDA
- Steve Q. Yang, Pfizer Global Research & Development
- Cathy Yang, RDPAC
- Zhimin Yang, M.D., SFDA, Center for Drug Evaluation
- Dan Zhang, Fountain Medical Development Ltd.
- Danyi Zhang, M.D., VitalStrategic Research Institute
- Kehong Zhang, M.D., Ph.D., Shanghai Standard Biotech Co. Ltd.
|
Impact China Partnerships
On May 4-6, 2008, hundreds of your colleagues and potential partners will be together in Beijing strategizing, designing and procuring their next great projects. By attending, you ensure that you will be on hand to meet with the industry leaders synonymous with Impact China. Ample time exists to build your contacts in the market and establish lasting relationships. Not to be missed conference activities include:
• Welcome to Beijing Cocktails: Sunday, May 4th, 2008
• Networking Gala Reception: Monday, May 5th, 2008
• Sea Turtle Showcase & Business Card Exchange: May 6th, 2008 (for full details, please click the link on your left)
Get Involved at Impact China IV
Are you looking to elevate your visibility in the Chinese market? Let us position you in front of over 300 leading executives with one of our exclusive sponsorship packages. Gear an event to your targeted market and raise your profile on the global stage. Opportunities are limited so get involved today. Please contact Henry Dicker at 212-967-0095 ext 263 or at hdicker@alm.com.
For media inquiries and partnerships, please contact Cheryl Kahan-Radhuber at 212-967-0095 ext 273 or at ckahanradhuber@srinstitute.com.
To submit a request to join the speaker faculty, please contact Judy Kelly at 212-967-0095 ext. 241 or at jkelly@srinstitute.com. |
Mailing List
